GLP-1 Drugs and AMD: What We’ve Learned So Far
(MedPage Today) — GLP-1 receptor agonists are being linked to a long list of benefits besides weight loss and diabetes, as evidence suggests they can lower the risk of conditions ranging from cancer and addiction to suicidal ideation, stroke…
Mechanisms of Glucagon‐Like Peptide 1 Receptor Agonist‐Induced Facial Lipodystrophy and a Path Toward Prevention
ABSTRACT Background The emergence of a distinct facial appearance characterized by pronounced hollowing of the cheeks, temples, chin, and periorbital region has become a noteworthy side effect of treatment with glucagon-like peptide 1 receptor agonists (GLP-1RAs). This phenomenon presents a growing concern in both dermatology and aesthetic medicine. The reduction of facial adipose tissue in […]
The fat jab mistake that can leave you ‘absolutely hammered’ – the booze-induced side effects & rule for new jabbers
HORRENDOUS hangovers are just one of the side effects that people taking fat jabs might experience during Christmas party season. But some GLP-1 mistakes could end up leaving users “absolutely hammered” – even well after your last drink. More than 1.5million prescriptions for weight loss drugs are being issued every month in the UK. By…
Fox News Health Newsletter: Common sleep problem tied to serious brain disorder
RESTLESS RISK — Common sleep problem tied to serious neurological disorder WARNING SIGNS — What to watch for after JFK’s granddaughter’s cancer diagnosis SOCIAL STRAIN — On a GLP-1? How to survive holiday meals without derailing your progress FAT BUSTER — New weight-loss shot shows promise, but experts urge caution SIGN UP FOR OUR HEALTH […]
Tirzepatide’s benefits fade for most: Weight and health markers rebound after withdrawal, study finds
Eli Lilly and Company, along with partner institutions in the US and United Kingdom, describe how short-term pharmacologic intervention does not appear to have lasting effects for most tirzepatide patients. People with obesity who lost weight on tirzepatide often regained at least 25% of that loss within a year of stopping treatment, along with reversals in improvements in waist circumference, blood pressure, lipids, and glycemic measures.
The Download: the mysteries surrounding weight-loss drugs, and the economic effects of AI
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. What we still don’t know about weight-loss drugs Weight-loss drugs have been back in the news this week. First, we heard that Eli Lilly, the company behind Mounjaro and Zepbound, became the first […]
Weight-loss drug doesn’t reduce risk of Alzheimer’s – new studies
Vitalii Vodolazskyi/Shutterstock.com Semaglutide, the drug behind the blockbuster weight-loss jabs Ozempic and Wegovy, does not slow cognitive decline in people with early-stage Alzheimer’s, according to two large new studies. The results close the door, for now, on hopes that a treatment for diabetes and obesity might also help protect the brain. The evoke and evoke+ […]
Here’s What is Affected Jack in the Box’s (JACK) Growth Plans
Prosper Stars & Stripes, a long/short equity fund, recently released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the third quarter of 2025, Prosper Stars & Stripes achieved a net return of +9.8%. In comparison, its long/short equity hedge fund peer group, as indicated by the HFRX Equity […]
The Era of Custom Weight-Loss Drugs Is Coming
“Ozempic is about to be old news,” my colleague Yasmin Tayag wrote in 2023, just before an even more powerful obesity drug, tirzepatide, then best known as Mounjaro, was approved. Well, two years later, Mounjaro is becoming old news, too. A whole slew of next-generation obesity drugs are on the horizon, some already advanced enough […]
IJMS, Vol. 26, Pages 11548: From Phytochemistry to Metabolic Regulation: The Insulin-Promoting Effects of Loureirin B Analogous to an Agonist of GLP-1 Receptor
IJMS, Vol. 26, Pages 11548: From Phytochemistry to Metabolic Regulation: The Insulin-Promoting Effects of Loureirin B Analogous to an Agonist of GLP-1 Receptor International Journal of Molecular Sciences doi: 10.3390/ijms262311548 Authors: Haowen Fang Xiaodong Sun Yanting Ding Siyuan Gu Bing Niu Qin Chen This study aimed to develop a potent, safe, and cost-effective small-molecule hypoglycemic […]